Cargando…

Hetero-bivalent nanobodies provide broad-spectrum protection against SARS-CoV-2 variants of concern including Omicron

SARS-CoV-2 variants with adaptive mutations have continued to emerge, causing fresh waves of infection even amongst vaccinated population. The development of broad-spectrum antivirals is thus urgently needed. We previously developed two hetero-bivalent nanobodies (Nbs), aRBD-2-5 and aRBD-2-7, with p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ma, Huan, Zhang, Xinghai, Zheng, Peiyi, Dube, Peter H., Zeng, Weihong, Chen, Shaohong, Cheng, Qingyu, Yang, Yunru, Wu, Yan, Zhou, Junhui, Hu, Xiaowen, Xiang, Yan, Zhang, Huajun, Chiu, Sandra, Jin, Tengchuan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Nature Singapore 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9334538/ https://www.ncbi.nlm.nih.gov/pubmed/35906408 http://dx.doi.org/10.1038/s41422-022-00700-3

Ejemplares similares

A bispecific nanobody dimer broadly neutralizes SARS-CoV-1 & 2 variants of concern and offers substantial protection against Omicron via low-dose intranasal administration
por: Ma, Huan, et al.
Publicado: (2022)

Potent Neutralization of SARS-CoV-2 by Hetero-Bivalent Alpaca Nanobodies Targeting the Spike Receptor-Binding Domain
por: Ma, Huan, et al.
Publicado: (2021)

A potent neutralizing antibody provides protection against SARS-CoV-2 Omicron and Delta variants via nasal delivery
por: Zhang, Xinghai, et al.
Publicado: (2022)

A potent and broad‐spectrum neutralizing nanobody for SARS‐CoV‐2 viruses, including all major Omicron strains
por: Yao, Hebang, et al.
Publicado: (2023)

Omicron-specific mRNA vaccine elicits potent immune responses in mice, hamsters, and nonhuman primates
por: Wu, Yi, et al.
Publicado: (2022)

Designing and Development of a Tandem Bivalent Nanobody against VEGF(165)
por: Khodabakhsh, Farnaz, et al.
Publicado: (2021)

Durability of Bivalent Boosters against Omicron Subvariants
por: Lin, Dan-Yu, et al.
Publicado: (2023)

Broadly neutralizing antibodies against Omicron-included SARS-CoV-2 variants induced by vaccination
por: Chi, Xiangyang, et al.
Publicado: (2022)

Effectiveness of Bivalent Boosters against Severe Omicron Infection
por: Lin, Dan-Yu, et al.
Publicado: (2023)

SARS-CoV-2 bivalent mRNA vaccine with broad protection against variants of concern
por: Ma, Qinhai, et al.
Publicado: (2023)

Harringtonine: A more effective antagonist for Omicron variant
por: Hu, Shiling, et al.
Publicado: (2023)

Three SARS-CoV-2 antibodies provide broad and synergistic neutralization against variants of concern, including Omicron
por: Wang, Siling, et al.
Publicado: (2022)

(Hetero)arene-fused boroles: a broad spectrum of applications
por: He, Jiang, et al.
Publicado: (2020)

A panel of nanobodies recognizing conserved hidden clefts of all SARS-CoV-2 spike variants including Omicron
por: Maeda, Ryota, et al.
Publicado: (2022)

A Bivalent Omicron-Containing Booster Vaccine against Covid-19
por: Chalkias, Spyros, et al.
Publicado: (2022)

Effect of hybrid immunity and bivalent booster vaccination on omicron sublineage neutralisation
por: Hoffmann, Markus, et al.
Publicado: (2023)

Neutralization of Omicron Subvariant BA.2.75 after Bivalent Vaccination
por: Chalkias, Spyros, et al.
Publicado: (2022)

Antibody Response to Omicron BA.4–BA.5 Bivalent Booster
por: Wang, Qian, et al.
Publicado: (2023)

Antiviral and bivalent vaccine efficacy against an omicron XBB.1.5 isolate
por: Uraki, Ryuta, et al.
Publicado: (2023)

Immunogenicity of Bivalent Omicron BA.4/5–Adapted Vaccine in Hemodialysis Patients
por: Anft, Moritz, et al.
Publicado: (2023)

Vaccine Confidence and Uptake of the Omicron Bivalent Booster in Tennessee: Implications for Vulnerable Populations
por: Alcendor, Donald J., et al.
Publicado: (2023)

Monovalent Omicron COVID-19 vaccine triggers superior neutralizing antibody responses against Omicron subvariants than Delta and Omicron bivalent vaccine
por: Li, Wanting, et al.
Publicado: (2023)

Decline of SARS-CoV-2-specific IgG, IgM and IgA in convalescent COVID-19 patients within 100 days after hospital discharge
por: Ma, Huan, et al.
Publicado: (2020)

Broad protective RBD heterotrimer vaccines neutralize SARS-CoV-2 including Omicron sub-variants XBB/BQ.1.1/BF.7
por: Zhang, Yanfang, et al.
Publicado: (2023)

Camel nanobodies broadly neutralize SARS-CoV-2 variants
por: Hong, Jessica, et al.
Publicado: (2021)

Broadly neutralizing and protective nanobodies against SARS-CoV-2 Omicron subvariants BA.1, BA.2, and BA.4/5 and diverse sarbecoviruses
por: Li, Mingxi, et al.
Publicado: (2022)

Bivalent omicron (BA.1) booster vaccination against SARS-CoV-2
por: Vasin, Andrey V, et al.
Publicado: (2023)

Bivalent COVID-19 mRNA vaccine against omicron subvariants in immunocompromised patients
por: Solera, Javier T, et al.
Publicado: (2023)

Dromedary camel nanobodies broadly neutralize SARS-CoV-2 variants
por: Hong, Jessica, et al.
Publicado: (2022)

A broadly neutralizing nanobody targeting the highly conserved S2 subunit of sarbecoviruses
por: Wang, Xiaoyun, et al.
Publicado: (2023)

Fusion-inhibition peptide broadly inhibits influenza virus and SARS-CoV-2, including Delta and Omicron variants
por: Zhao, Hanjun, et al.
Publicado: (2022)

Broad-spectrum humanized monoclonal neutralizing antibody against SARS-CoV-2 variants, including the Omicron variant
por: Wen, Kun, et al.
Publicado: (2023)

A potent synthetic nanobody with broad-spectrum activity neutralizes SARS-CoV-2 virus and the Omicron variant BA.1 through a unique binding mode
por: Zhao, Dongping, et al.
Publicado: (2022)

Selection of diverse strains to assess broad coverage of the bivalent FHbp meningococcal B vaccine
por: Harris, Shannon L., et al.
Publicado: (2020)

Characterization of SARS-CoV-2-specific antibodies in COVID-19 patients reveals highly potent neutralizing IgA
por: Zeng, Weihong, et al.
Publicado: (2021)

Developing Next‐Generation Protein‐Based Vaccines Using High‐Affinity Glycan Ligand‐Decorated Glyconanoparticles
por: Gao, Yanan, et al.
Publicado: (2022)

Characteristic analysis of Omicron‐included SARS‐CoV‐2 variants of concern
por: Yang, Hao, et al.
Publicado: (2022)

Shark nanobodies with potent SARS-CoV-2 neutralizing activity and broad sarbecovirus reactivity
por: Chen, Wei-Hung, et al.
Publicado: (2023)

Structural Basis for Recognition of Human Enterovirus 71 by a Bivalent Broadly Neutralizing Monoclonal Antibody
por: Ye, Xiaohua, et al.
Publicado: (2016)

Research Progresses and Applications of Fluorescent Protein Antibodies: A Review Focusing on Nanobodies
por: Chen, Yu-Lei, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_9oavm4ut1ku5rp0un1h34658l0